Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Common Equity: 2021-2025

Historic Common Equity for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $1.1 billion.

  • Krystal Biotech's Common Equity rose 28.45% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 28.45%. This contributed to the annual value of $946.4 million for FY2024, which is 21.54% up from last year.
  • Krystal Biotech's Common Equity amounted to $1.1 billion in Q3 2025, which was up 9.34% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Common Equity ranged from a high of $1.1 billion in Q3 2025 and a low of $408.2 million during Q3 2021.
  • For the 3-year period, Krystal Biotech's Common Equity averaged around $846.4 million, with its median value being $838.9 million (2024).
  • In the last 5 years, Krystal Biotech's Common Equity declined by 12.02% in 2022 and then skyrocketed by 63.26% in 2024.
  • Over the past 5 years, Krystal Biotech's Common Equity (Quarterly) stood at $593.6 million in 2021, then dropped by 12.02% to $522.2 million in 2022, then soared by 49.10% to $778.6 million in 2023, then increased by 21.54% to $946.4 million in 2024, then increased by 28.45% to $1.1 billion in 2025.
  • Its Common Equity stands at $1.1 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $984.7 million for Q1 2025.